Talphera, Inc.
制药业
San Mateo,California 3,620 位关注者
Focused on the development and commercialization of innovative therapies for use in medically supervised settings
关于我们
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra?, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
- 网站
-
https://www.talphera.com
Talphera, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 51-200 人
- 总部
- San Mateo,California
- 类型
- 上市公司
- 创立
- 2005
- 领域
- pharmaceuticals、research & development和pain management
地点
-
主要
1850 Gateway Dr
US,California,San Mateo,94404